Liu et al., 2016 - Google Patents
Discovery of pyrazolo [1, 5-a] pyrimidine TTK inhibitors: CFI-402257 is a potent, selective, bioavailable anticancer agentLiu et al., 2016
View HTML- Document ID
- 16231770293736946218
- Author
- Liu Y
- Laufer R
- Patel N
- Ng G
- Sampson P
- Li S
- Lang Y
- Feher M
- Brokx R
- Beletskaya I
- Hodgson R
- Plotnikova O
- Awrey D
- Qiu W
- Chirgadze N
- Mason J
- Wei X
- Lin D
- Che Y
- Kiarash R
- Fletcher G
- Mak T
- Bray M
- Pauls H
- Publication year
- Publication venue
- ACS Medicinal Chemistry Letters
External Links
Snippet
This work describes a scaffold hopping exercise that begins with known imidazo [1, 2-a] pyrazines, briefly explores pyrazolo [1, 5-a][1, 3, 5] triazines, and ultimately yields pyrazolo [1, 5-a] pyrimidines as a novel class of potent TTK inhibitors. An X-ray structure of a …
- 230000002401 inhibitory effect 0 title abstract description 128
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulfur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Discovery of pyrazolo [1, 5-a] pyrimidine TTK inhibitors: CFI-402257 is a potent, selective, bioavailable anticancer agent | |
Kusakabe et al. | Discovery of imidazo [1, 2-b] pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity | |
Mao et al. | Overview of research into mTOR inhibitors | |
Goldberg et al. | The Discovery of 7-Methyl-2-[(7-methyl [1, 2, 4] triazolo [1, 5-a] pyridin-6-yl) amino]-9-(tetrahydro-2 H-pyran-4-yl)-7, 9-dihydro-8 H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor | |
Pike et al. | The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino) propoxy] pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1, 3-dihydro-2 H-imidazo [4, 5-c] quinolin-2-one) | |
Jorda et al. | Pyrazolo [4, 3-d] pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity | |
Degorce et al. | Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of ataxia telangiectasia mutated (ATM) kinase | |
Ward et al. | Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2 | |
Paruch et al. | Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases | |
Zask et al. | ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines | |
Toogood et al. | Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 | |
Saurat et al. | Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors | |
Huang et al. | Discovery of ZN-c3, a highly potent and selective Wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer | |
Tao et al. | Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors | |
Xu et al. | Synthesis and biological evaluation of pyrazolo [1, 5-a] pyrimidine compounds as potent and selective Pim-1 inhibitors | |
Gucky et al. | A novel series of highly potent 2, 6, 9-trisubstituted purine cyclin-dependent kinase inhibitors | |
Jain et al. | Discovery of potent and selective RSK inhibitors as biological probes | |
Schulze et al. | Treating cancer by spindle assembly checkpoint abrogation: discovery of two clinical candidates, BAY 1161909 and BAY 1217389, targeting MPS1 kinase | |
Patel et al. | 2, 4, 6-Triaminopyrimidine as a novel hinge binder in a series of PI3Kδ selective inhibitors | |
Woodward et al. | Introduction of a Methyl Group Curbs Metabolism of Pyrido [3, 4-d] pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N 2-(2-Ethoxy-4-(4-methyl-4 H-1, 2, 4-triazol-3-yl) phenyl)-6-methyl-N 8-neopentylpyrido [3, 4-d] pyrimidine-2, 8-diamine (BOS172722) | |
Pei et al. | Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349 | |
Ren et al. | Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2 | |
Innocenti et al. | Rapid discovery of pyrido [3, 4-d] pyrimidine inhibitors of monopolar spindle kinase 1 (MPS1) using a structure-based hybridization approach | |
Gangjee et al. | 2-Amino-4-oxo-5-substituted-pyrrolo [2, 3-d] pyrimidines as Nonclassical Antifolate Inhibitors of Thymidylate Synthase1a, b | |
Liu et al. | Development of alkyne-containing pyrazolopyrimidines to overcome drug resistance of Bcr-Abl kinase |